GPRC5D and Miyoshi myopathy: Preliminary clinical trial results have also shown that the first-in-class GPRC5D-targeted CAR T cell therapy for MM has a manageable safety profile with no serious or unexpected toxicities; this dose escalation study is ongoing with additional patients planned for treatment at higher doses.